AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

By Maggie Fick and Danilo Masoni LONDON (Reuters) -AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop ...

Sir Ed Davey said the company's decision to pause plans to invest £200m at the city's biomedical campus was "deeply troubling ...

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

The company has shelved plans for a research facility in Cambridge, a move that follows the drugmaker in January scrapping an ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

AstraZeneca in January also stopped its $610 million plans to construct a vaccine R&D and manufacturing site in the U.K.

AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England, research site, a ...

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and ...

If your portfolio has any shade of science or healthcare, odds are AstraZeneca has crossed your radar. The stock’s been a ...

In today's Pharmalittle roundup, we're reading about FDA targeting Hims & Hers, AstraZeneca halting U.K. investment, and much ...